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Joubert syndrome (JS) is an autosomal recessive disorder,
consisting of mental retardation, cerebellar vermis aplasia, an
irregular breathing pattern, and retinal degeneration.
Nephronophthisis (NPHP) is found in 17–27% of these
patients, which was designated JS type B. Mutations in four
separate genes (AHI1, NPHP1, CEP290/NPHP6, and MKS3) are
linked to JS. However, missense mutations in a new ciliary
gene (RPGRIP1L) were found in type B patients. We analyzed
a cohort of 56 patients with JS type B who were negative for
mutations in three (AHI1, NPHP1, and CEP290/NPHP6) of the
four genes previously linked to the syndrome. The 26 exons
encoding RPGRIP1L were analyzed by means of PCR
amplification, CEL I endonuclease digestion, and subsequent
sequencing. Using this approach, four different mutations in
the RPGRIP1L gene in five different families were identified
and three were found to be novel mutations. Additionally, we
verified that missense mutations are responsible for JS type B
and cluster in exon 15 of the RPGRIP1L gene. Our studies
confirm that a T615P mutation represents the most common
mutation in the RPGRIP1L gene causing disease in about
8–10% of JS type B patients negative for NPHP1, NPHP6, or
AHI1 mutations.
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Joubert syndrome (JS (MIM 213300)) is a developmental
disorder characterized by cerebellar ataxia, mental retarda-
tion, oculomotor apraxia, hypotonia, and neonatal tachy-
pnea.1,2 Subtypes of JS, which are termed Joubert syndrome
and related disorders, include further clinical features such as
nephronophthisis (NPHP), retinal dystrophy, ocular colo-
boma, hepatic fibrosis, occipital encephalocele, and polydactyly.
The prevalence of JS is estimated as 1:100 000.3 The ‘molar
tooth sign’ (MTS) represents the classical neuroradiological
feature, caused by cerebellar vermis aplasia, thickened and
elongated superior cerebellar peduncles, and a deepened
interpeduncular fossa.4 In 17–27% of patients with JS, renal
involvement with NPHP and retinitis pigmentosa (RP) is
reported.5 This subgroup of patients with JS is called JS type
B or cerebello-oculo-renal syndrome patients.6 NPHP (MIM
256100) constitutes the most frequent genetic cause of end-
stage renal disease (ESRD) in children and young adults.7
The characteristic histological findings in NPHP are renal
interstitial fibrosis, interstitial cell infiltrates, and tubular
atrophy with cyst development at the corticomedullary
border.7 Retinal degeneration occurs in 10–15% of NPHP
patients, which results in the Senior–Loken syndrome.
Four genes are known to cause JS: AHI1 on chromosome
6q23.3,8,9 NPHP1 on chromosome 2q13,10 CEP290/NPHP6
on chromosome 12q21.3,11,12 and MKS3 on chromosome
8q24.13 Mutations in the AHI1 gene are causative in 10–15%
of patients with Joubert syndrome and related disorders,2
who often present with retinal dystrophy. NPHP was found
only in a few older subjects with AHI1 mutations.10,14
NPHP1 deletions are found in approximately 25% of NPHP
patients,15 whereas NPHP1 deletions are found only in 1–2%
of all JS patients. However, neurological involvement
compatible with JS type B was detected in 8.9% of all
NPHP1-deletion carriers retrospectively.16 In a recent pub-
lication, CEP290/NPHP6 mutations were found in 43% of JS
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type B patients and only in 2% of a cohort of JS
patients without retinal involvement.17 Mutations in
CEP290/NPHP6 were also found in patients with Leber’s
congenital amaurosis (LCA) and in patients with Meckel–-
Gruber syndrome (MKS).18,19 Whereas LCA patients show
only an ocular phenotype, MKS represents a rare autosomal
recessive severe disorder, characterized by multicystic kidney
dysplasia, polydactyly, and liver bile duct proliferation.
Typical features of MKS such as occipital encephalocele and
polydactyly were also reported in some patients with JS.19
Mutations in the MKS3 gene were found in MKS patients as
well as in 3 out of 22 (approximately 10%) JS patients.13
Finally, two other JS loci with yet unidentified genes were
found on chromosome 9q34.3 and on chromosome
11p12–11q13.3.20,21
Very recently, mutations in the RPGRIP1L gene were
found and the RPGRIP1L gene was identified as a new gene
causing JS type B.22 Using a homozygosity approach, a 1.6-
Mb region was defined encompassing the deleted genetic
region causing the ft/ (fused toe) phenotype in mice. The
characteristics of the ft/ mouse are (i) fusion of digits 1–3
and polydactyly, (ii) an enlarged thymus, (iii) a very small
mesencephalon and telencephalon with exencephaly, (iv)
microphthalmia, and (v) laterality defects.23 Only recently,
cystic kidney disease was reported in the ft/ mouse.22 The
central nervous system phenotype of the ft/ mouse is
reminiscent of the central nervous system phenotype of JS
patients. The finding that RPGRIP1L was located within the
deletion of the ft/ mouse led to the discovery of RPGRIP1L
mutations as the cause of NPHP type 8. In addition, recently,
RPGRIP1L was shown to interact with NPHP4, thereby
indicating a function of RPGRIP1L in the complex of other
nephrocystins and outlining RPGRIP1L as a promising
candidate gene for NPHP.24
Interestingly, a clinical overlap between JS and MKS in
humans was confirmed with the discovery of the RPGRIP1L
gene: in JS patients, missense mutations or the presence of
only one truncating mutation was found, whereas two
truncating mutations were identified in the more severe
MKS phenotype.22 RPGRIP1L encodes a protein expressed in
primary cilia, which is compatible with the ciliary theory of
cystic kidney disease.22,25 The genes causative for NPHP and
MKS were also shown to be expressed in renal primary
cilia.26,27 To see how frequent mutations in RPGRIP1L are
responsible for JS type B, we analyzed a cohort of 56 patients
from central Europe and the United States with JS type B,
who were all negative for homozygous NPHP1 deletions and
mutations in AHI1 and CEP290/NPHP6. All 26 exons
encoding the RPGRIP1L gene were analyzed by the CEL I
assay, and aberrant bands were subsequently sequenced.15
RESULTS
Clinical data
The five kindreds presenting with RPGRIP1L mutations
included six living individuals affected with NPHP and
neurological symptoms compatible with JS (JS type B)
(Table 1). All six patients had impaired renal function. ESRD
ensued between 4 and 21 years of age (Table 1). Renal biopsy
was available in four out of the six patients. Brain imaging by
magnetic resonance imaging (MRI) was available in three of
the six patients, who all showed MTS and CVA (Table 1). One
patient presented with pituitary agenesis (A1183 II-1).
Mental retardation was found in all patients. Other
neurological phenotypes included (i) alalia (1/6), (ii) delayed
speech development (1/6), and (iii) gait problems (2/6)
(Table 1). Ocular motor apraxia type Cogan was found in
one out of six patients, ocular coloboma was found in one
out of six patients and unspecified ‘vision problems’ were
Table 1 | Synopsis of the clinical data, current age, age at ESRD, extrarenal manifestations, mutation, and amino-acid change in


























10 + + +  + Alalia 15 c.1843A4C, H T615P (Armadillo)
A762 II-3 German 10 + + +  + 15 c.1897T4C, H C633R (Dr)







23 IVS23-2A4G, h Obligatory
splice-site defect
F631 II-1 29 German 21 +  + + ND Ocular coloboma 10 c.1177G4A, h (P) E393K (Dr)
CVA, cerebellar vermis aplasia; ESRD, end-stage renal disease; fs, frameshift; IVS, intervening sequence; LF, liver fibrosis; MR, mental retardation; ND, not determined; NPHP,
nephronophthisis; OMA, ocular motor apraxia type Cogan.
aAll mutations were absent from 496 healthy control subjects.
bAge of onset of ESRD.
cH, homozygous; h, heterozygous; M, maternal; P, paternal; no specification if parent DNA not available for mutational analysis.
dSpecies dating back farthest in evolution, in which the amino-acid residue of the wild-type allele is conserved, Dr, Danio rerio.
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described in one patient (A166 II-3). No retinal defects were
found in five of the six patients. However, the unspecified
vision problem in A166 II-3 does not exclude a retinal
involvement in this patient. Liver fibrosis was described in
two out of six patients (F631 II-1 and A1183 II-1). One of the
six patients, A1183 II-1, developed a myofibroblastic
abdominal tumor.
The clinical phenotypes are described specifically as
follows:
Family A166. Patient A166 II-3 is an 8-year-old daughter
of a consanguineous North American family. One of her
brothers died with ESRD during infancy. She presented with
ESRD at the age of 4 years. After initial resuscitation, a kidney
biopsy was performed and was compatible with NPHP. Renal
ultrasound (US) showed diffuse increased echotexture and
loss of corticomedullary differentiation. She also presented
with developmental delay (e.g., delayed speech development)
and gait problems. She was able to walk at the age of 2 years.
In addition, ‘vision problems’ were reported but were not
specified by the pediatrician. Interestingly, an MRI did not
show an ‘MTS’ in her case. Her 5 years younger brother is
also developmentally delayed. He has a reduced glomerular
filtration rate and polyuria. His renal biopsy was consistent
with NPHP. His MRI revealed the MTS. No blood sample for
molecular analysis was available in his case.
Family F138. Both affected siblings (F138 II-1 and II-2)
descend from a Swiss kindred. Patient II-1 is a 22-year-old
male patient who was diagnosed with JS and presented with
ESRD at the age of 10 years. He required resuscitation when
first symptoms of ESRD appeared. His renal biopsy showed
atrophic tubules with thickened basement membranes.
Moreover, the tubules showed microcysts. Interstitial inflam-
mation was seen at the corticomedullary border (Figure 1).
He received a kidney transplant from his father at the age of
11 years. Additional symptoms in sibling II-1 were cerebellar
vermis hypoplasia, ocular apraxia, mental retardation, and
delayed language skills. The brain MRI showed a slightly
dilated fourth ventricle and a completely missing cerebellar
vermis. Interestingly, no retinal defect was noted. While II-1
is able to ride a bike, his sister is affected much more severely.
For example, she is unable to walk due to severe muscle
hypotonia and hypotrophy. She also suffers from mental
retardation. Her renal US showed hyperechogenic texture
and small kidneys with multiple cysts, compatible with
NPHP.
Family A762. Patient A762 II-3 is a 12-year-old male
offspring from a consanguineous German kindred. He
presented with ocular motor apraxia type Cogan at the age
of 4 months and with ESRD at the age of 10 years. Kidney
biopsy revealed tubulointerstitial infiltrates and tubular
microcysts (Figure 1b). Renal US showed no corticomedul-
lary differentiation and hyperechogenic texture. Further
symptoms were mild mental retardation, muscular hypoto-
nia, and gait problems due to ataxia. MRI imaging of the
brain was performed in the follow-up and revealed an MTS
and thickened superior cerebellar peduncles, thus confirming
the diagnosis of JS. Interestingly, no retinal dysfunction was
reported.
Family A1183. A1183 II-1 is a 7-year-old male patient
from Germany, who was diagnosed with JS. His symptoms
included mental retardation, cerebellar vermis aplasia,
pituitary agenesis, liver fibrosis, and impaired renal function.
As a consequence of his pituitary agenesis, he has pituitary
insufficiency and receives hormonal replacement therapy
with growth hormone, hydrocortisone, and thyroxin. Ima-
ging studies by MRI did not reveal any pituitary tissue in the
sella. Liver fibrosis was detected by clinical symptoms of
esophageal varices and was confirmed by liver biopsy. The
renal US showed enlarged kidneys with hyperechogenic
texture. Renal biopsy revealed focal tubular atrophy, inter-
stitial fibrosis, and few tubular microcysts. His renal function
remains stable, and he does not need dialysis. In addition,
this patient developed an abdominal myofibroblastic tumor.
No ocular phenotype was reported. No other family
members are affected.
Family F631. F631 II-1 is a 29-year-old male patient from
Germany, who presented with mental retardation, ocular
coloboma, liver fibrosis, and ESRD. Liver fibrosis was
confirmed by liver biopsy. No other family members are
affected. Renal US revealed small hyperechogenic kidneys.
Mutation analysis
The CEL I assay was recently shown to be highly sensitive for
mutational analysis by detecting 92% of known NPHP
mutations (73 out of 79 mutations).15 The strength of the
CEL I mutation detection assay using celery extract is its
simplicity, effectiveness, and inexpensiveness. CEL I is
extremely stable during the purification process, during the
storage period at 201C, and during the whole assay. In the
CEL I assay, 298 out of 1456 PCR products resulted in an
aberrant band and were subsequently sequenced. In our
cohort of 56 JS type B patients, we detected three missense
and one splice-site mutation in five kindreds (Figure 2). In
addition, two individuals of this cohort (A166 II-3 and A762
II-1) were found to be homozygous in the RPGRIP1L region
due to 50K single nucleotide polymorphism data. In A166 II-
3, the previously published c.1843A4C (T615P) mutation
was identified (Figure 2a). We detected the same mutation in
a b
Figure 1 | Histopathology in patients with RPGRIP1L mutations.
Histopathology from patient F138 II-1 (a) and patient A762 II-3
(b) showed the characteristic triad of NPHP with interstitial fibrosis,
patchy lymphocytic infiltrate, cystic dilation of tubules, and tubular
basement membrane disruption. Hematoxylin–eosin, original
magnification  50.
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two affected siblings of kindred F138 (II-1 and II-2)
(Figure 2b). The amino acid threonine at position 615 is
evolutionarily conserved down to armadillo. In individual
A762 II-1, we found a new homozygous c.1897T4C
(C633R) missense mutation in exon 15 (Figure 2c). The
amino acid cysteine at position 633 is evolutionarily
conserved to zebrafish. The finding that mutations in A166
II-3 and A762 II-1 are homozygous is in accordance with
known consanguinity. Both mutations are located in the first
C2 domain of RPGRIP1L. We also identified two novel
heterozygous mutations: (i) in A1183 II-1, an obligatory
splice acceptor site of exon 23 (IVS23-2A4G) was shown to
be altered (Figure 2d); and (ii) in F631 II-1, the missense






































Figure 2 | Pedigrees and results of the mutational analysis in all kindreds with RPGRIP1L mutations. Circles denote females and squares
denote males. Filled symbols denote affected individuals and crosshatches denote deceased individuals. Roman numerals denote generations.
Arrows denote individuals in whom DNA was available for haplotype analysis. The upper sequence shows the wild-type (WT) sequence and the
lower sequence reveals the mutation (MUT) in each family. The resulting amino acids are indicated below sequences. Mutations in (a–c) are
located in exon 15. (a and b) In affected individuals of kindreds A166 (II-3) and F138 (II-1 and II-2), a homozygous c.1843A4C was detected
resulting in a T615P amino-acid exchange. (c) The affected individual II-3 in family A762 showed a homozygous c.1897T4C substitution,
causing a C633R change. (d) The affected subject II-1 in A1183 carried a heterozygous splice-site mutation IVS23-2A4G at a 100% conserved
site. (e) The affected individual II-1 in family F631 showed a heterozygous c.1177G4A substitution, causing an E393K change. The altered
nucleotides are indicated by an arrowhead, and the altered amino acid is underlined in the WT and is in red and underlined in the mutated
sequence.
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inherited from the father) was identified (Figure 2e). The
splice-site mutation IVS23-2A4G in A1183 II-1 is 100%
conserved. RNA of this individual is not available. Because
only one mutation was found in A1183 II-1 and F631 II-1
using the CEL I assay, all other exons of RPGRIP1L were
directly sequenced in these individuals. However, no second
mutation was found. As part of the mutational analysis, 11
single nucleotide polymorphisms (SNPs) of the RPGRIP1L
gene, which are distributed all over the gene, were analyzed.
Interestingly, for A1183 and F631, all 11 SNPs appear
homozygous. This may indicate a larger heterozygous
deletion with hemizygosity for these SNPs. None of the
mutations were found in the 100 healthy controls. Therefore,
mutations detected by us are unlikely to be common
polymorphisms and are most likely disease causing. Finally,
using the CEL I assay, multiple new SNPs in the RPGRIP1L
gene were identified (data available from the authors).
DISCUSSION
Very recently, mutations in RPGRIP1L were published as a
new cause of JS type B and MKS.22 The first publication of
mutations in the RPGRIP1L gene lists six different mutations
in five JS type B patients.22 We performed mutational analysis
in a cohort from central Europe and North America of 56 JS
type B patients, using the CEL I assay to determine how
frequent mutations in the RPGRIP1L gene in JS type B occur.
By this approach, we identified four different mutations in
the RPGRIP1L gene in five different families. Three of the
four mutations were novel.
In the case of RPGRIP1L, a clear genotype–phenotype
correlation seems to exist, with only one truncating mutation
or a homozygous missense mutation causing JS type B,
whereas homozygous truncating mutations cause MKS.22 We
are able to confirm that nontruncating mutations of the
RPGRIP1L gene are disease causing for JS type B, because we
identified only missense mutations but no truncating
mutations.
Although the number of patients with mutations in our
cohort is limited, a spectrum of different phenotypes was
identified in association with mutations in RPGRIP1L.
Whereas developmental delay and NPHP were found in all
patients, other symptoms occurred more rarely (e.g., liver
fibrosis and OMA) (Table 1). Surprisingly, individual A1183
II-1 revealed pituitary agenesis, indicating a potential clinical
overlap with RHYNS syndrome (retinitis pigmentosa,
hypopituitarism, NPHP, and skeletal dysplasia). Interestingly,
in our six patients with RPGRIP1L mutations, RP was
described in only one. Delous et al.22 also described only one
RPGRIP1L patient with RP, whereas almost all NPHP6
patients had RP. We confirm in our patients the rare
association of RP and mutations in RPGRIP1L.
In three individuals, we found the previously identified
c.1843A4C (T615P) mutation in a homozygous state. In the
previous publication of Delous et al.,22 the c.1843A4C
(T615P) mutation occurred in two patients only hetero-
zygously. By immunoprecipitation, reduced interaction of the
T615P mutant protein with nephrocystin-4 was demon-
strated.22 The T615P mutation and the new homozygous
C633R mutation are both located in the C2 domain of the
RPGRIP1L protein, close to the nephrocystin-4-interacting
region. Four of our six patients harbor homozygous
mutations in exon 15. Including the previously published
data, the highest number of mutations in RPGRIP1L are
found in exon 15, with the c.1843A4C (T615P) mutation
representing the most common mutation. This may indicate
that the c.1843A4C (T615P) mutation is a putative founder
mutation.
Surprisingly, we also detected two heterozygous mutations
in two different individuals (A1183 II-1 and F631 II-1).
Sequencing of all other RPGRIP1L exons did not reveal a
second disease-causing mutation. We may have missed a
second mutation that may be located in an intron. The
second heterozygous mutation identified in A1183 affects a
conserved splice site at IVS23-2A4G. Exon 23 encodes the
RID domain (domain with homology to the RPGR-
interacting domain of RPGRIP) of the RPGRIP1L protein.
This mutation is highly likely to be involved in the
pathogenesis of JS type B, as a 100% conserved splice site
is altered, affecting an essential protein domain. Surprisingly,
other authors have also reported a lack of a second mutation
in up to 20% of their patients in other JS- or NPHP-causing
genes like MKS3 or CEP290/NPHP6.13,17,19 A missing second
mutation seems to become a more common phenomenon
and may be explained by oligogenic inheritance as observed
in Bardet–Biedl syndrome, which shares a significant
phenotypic overlap with NPHP and JS.28 More and more
indications have accumulated for an oligogenic inheritance in
JS and NPHP.29,30 Therefore, in patients with only one
mutation in RPGRIP1L, additional digenic mutations may be
located in another disease-related gene.
The variety of disorders associated with mutations in
other JS-causing genes such as CEP290/NPHP6 is astonish-
ing. Mutations in CEP290 were identified to be the most
frequent cause for LCA.31 In addition, CEP290 mutations
were found in patients with JS.11,12 Finally, CEP290
mutations were described in patients with the severe MKS
phenotype.19 The milder LCA phenotype, affecting the eyes
only, was shown to be due to the activation of a cryptic splice
site in intron 26 (c.2991þ 1655A4G), causing low levels of
wild-type transcripts from the mutant allele.18 This hypoth-
esis was an attempt to explain why the more severe JS
phenotype did not occur in LCA individuals. However,
recently, truncating mutations in CEP290 were published in
10 families with LCA, questioning this explanation.31 The
spectrum of patients with CEP290/NPHP6 mutations repre-
sents a clinical continuum, ranging from isolated eye disease
(RP) to a potentially lethal multiorgan disorder (MKS).
Surprisingly, the same variability of phenotypes (e.g., JS and
MKS) can be found in patients with RPGRIP1L mutations,
and allelism for JS and MKS was described again.22
Identification of the nephrocystins 1–8 by positional
cloning has contributed to the unifying concept that all
1524 Kidney International (2007) 72, 1520–1526
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proteins mutated in cystic kidney disease are expressed in
primary cilia, centrosomes, or basal bodies of renal epithelial
cells.25,32 Moreover, a potential role in mechanosensing,
cellular signaling, or in intraflagellar transport is discussed, as
most nephrocystins are expressed in cilia.7,33 Interaction of
the AHI1 protein with nephrocystin-1 was shown pre-
viously.34 The gene products of MKS1 and MKS3 were also
shown to be expressed in cilia.27 Recently, a list of over 2000
ciliary proteins in retinal epithelial cells was published
containing most of the JS and NPHP disease-causing genes,35




We obtained blood samples, pedigrees, and clinical information after
receiving informed consent (http://www.renalgenes.org) from 56
patients/families with JS and NPHP (JS type B). Approval for
experiments on humans was obtained from the University of
Michigan Institutional Review Board. In all patients, the diagnosis
NPHP was based on the following criteria: (i) clinical course with
characteristic clinical signs of chronic renal failure, polyuria,
polydipsia, anemia, and growth retardation; (ii) renal US or renal
biopsy compatible with the diagnosis of NPHP as judged by a
(pediatric) nephrologist; and (iii) pedigree compatible with auto-
somal recessive inheritance.
Genome-wide linkage screen
A genome-wide homozygosity mapping was performed for A166 II-
1 and A762 II-1 using 50K Affymetrix SNP arrays. Data were
evaluated by performing multipoint nonparametric lod scores across
the whole genome using GENEHUNTER software assuming
recessive inheritance. Areas of homozygosity were confirmed by
haplotype analysis with microsatellite markers.
PCR amplification and sequencing
All 26 exons encoding RPGRIP1L were individually amplified using
exon-flanking primers (sequences are available upon request). A 10-ml
PCR was set up with 10 ng genomic DNA, 10 pmol each of forward
and reverse primers, and 5ml of HotStarTaqPolymerase mixture
(Qiagen, Valencia, CA, USA). DNA amplification was performed on a
thermal cycler (Mastercycler; Eppendorf, Hamburg, Germany, USA)
using Thermo-Fast 96-well plates (ABgene, Rochester, NY, USA) and
applying the same touchdown PCR protocol for amplifying all exons
or microsatellite markers. The following touchdown PCR protocol
was used: initial denaturation at 941C for 15 min, followed by 20
cycles with an annealing temperature decreasing by 0.71C per cycle,
starting at 721C for 30 s, denaturation at 941C for 30 s, and extension
at 721C for 1 min. An additional 20 cycles were added: 941C for 30 s,
551C for 30 s, and 721C for 1 min with a final extension of 721C for
10 min. For mutational screening, 2ml PCR products were directly
used in a CEL I endonuclease digest. For sequencing, PCR products
were purified using spin columns according to the manufacturer’s
instructions (Marligen, Ijamsville, MD, USA) and directly sequenced
using the dideoxy chain termination method on an automatic
capillary genetic analyzer (Applied Biosystems, Foster City, CA, USA).
As part of the mutational analysis, 11 SNPs of the RPGRIP1L gene,
which are distributed all over the gene, were documented. Eight of
these SNPs were already published (rs35526952, rs4133018,
rs7192060, rs2302677, rs7203525, rs2111119, and rs3213758), and
three SNPs were found to be new (IVS5-29G4A, c.1351G4A, and
IVS13þ 162G4C).
CEL I endonuclease preparation, heteroduplex formation,
and CEL I treatment
Preparation of the CEL I endonuclease, heteroduplex formation,
and CEL I treatment were performed as previously described by
Otto et al.15
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